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Apical left ventricular assist device specimen
Immunohistochemistry
Next-generation sequencingPhospholamban (PLN) p.Arg14del cardiomyopathy is associated with an increased risk of malignant ventricular
arrhythmias and severe heart failure and a poor prognosis from late adolescence. It can be diagnosed in whole
heart specimens, but rarely in right ventricular biopsy specimens, by PLN immunohistochemistry showing
PLN-containing aggregates concentrated in cardiomyocytes in dense perinuclear aggresomes. The purpose of
this studywas to determinewhether PLN immunohistochemistry can beused to diagnose PLNp.Arg14del cardio-
myopathy using apical left ventricular myocardial specimens harvested during left ventricular assist device
(LVAD) implantation. At that stage, a genetic diagnosis, whichmay guide treatment and referral of family mem-
bers for further investigation, is frequently not established yet. Included were myocardial specimens from 30 di-
verse genetic cardiomyopathy caseswith known variants (9 carriers of the pathogenic PLNp.Arg14del variant, 18
cases with other pathogenic or likely pathogenic variants in cardiomyopathy-related genes, and 3 with only var-
iants of unknown signiﬁcance). Immunohistochemical analysis revealed typical dense perinuclear globular PLN-
positive aggregates, representing aggresomes, in all nine PLN p.Arg14del cases. In 20 non-PLN cases, PLN-staining
was absent. In one non-PLN case, one of the two independent observers misinterpreted PLN staining of heavily
wrinkled nuclear membranes of cardiomyocytes as perinuclear PLN aggregates. In this genetic cardiomyopathy
cohort, PLN Immunohistochemical analysis in LVAD biopsies was found to be a highly sensitive (100%) and spe-
ciﬁc (95%) method for demonstration of PLN protein aggregates in PLN p.Arg14del cardiomyopathy. In clinical
practice, PLN immunohistochemical analysis of LVAD specimens can be of incremental value in the diagnostic
workup of this cardiomyopathy, even more so if genetic analysis is not readily available.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).; ARVC, Arrhythmogenic right ventricular cardiomyopathy; DCM, Dilated cardiomyopathy; IHC, Immunohistochemistry; LVAD,
ncing; PLN, Phospholamban; RVEMB, Right ventricular endomyocardial biopsy; SERCA, Sarcoplasmic Reticulum Ca2+-ATPase;
e Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (The Hague, the
OSIS and CVON 2015–12 eDETECT projects. Folkert W. Asselbergs is supported by a Dekker scholarship-Junior Staff Member
iversity College London Hospitals National Institute for Health Research Biomedical Research Centre. The funding sources had
, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
in the research and/or article preparation and have approved the ﬁnal article.
etics, Cardiology and Pathology, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Overview of observed genetic variants using targeted NGS (n=30 cases)
Case Gene cDNA sequence Protein sequence Class [13]
1 CRYAB c.527ANG p.(Ter176Trpext*19) (L)P
2 PLN c.40_42delAGA p.(Arg14del) P
3 PLN c.40_42delAGA p.(Arg14del) P
4 LMNA c.992GNA p.(Arg331Gln) P
5 TNNT2 c.650_652del p.(Lys217del) P
6 PLN c.40_42delAGA p.(Arg14del) P
7 TTN c.47756_47757del p.(Lys15919Serfs*3) LP
8 LMNA c.949GNA p.(Glu317Lys) LP
9 TTN c.32810CNT p.(Pro10937Leu) VUS
TTN c.13739ANG# p.(His4580Arg#) VUS
10 TTN c.61121_1GNA p.(Glu2374Glyfs*7) LP
11 PLN c.40_42delAGA p.(Arg14del) P
12 MYBPC3 c.187CNG p.(His63Asp) VUS
13 TTN c. 92322_92326del p.(Ser30776Hisfs*7) LP
14 LMNA c.1608+4ANG^ p.? [16] P
15 LMNA c.992GNA p.(Arg331Gln) P
16 TTN c. 81610GNT p.(Glu27204*) LP
17 TTN c. 69748GNT p.(Glu23250*) P
18 LMNA c.1130GNT p.(Arg377Leu) P
19 TPM1 c.479GNA p.(Arg160His) LP
20 LMNA c.1477CNT p.(Gln493*) P
21 TPM1 c.184GNC p.(Glu62Gln) P
22 PLN c.40_42delAGA p.(Arg14del) P
23 MYH7 c.2573GNT p.(Arg858His) VUS
24 PLN c.40_42delAGA p.(Arg14del) P
25 PLN c.40_42delAGA p.(Arg14del) P
26 DSP c.6687delA p.(Arg2229Serfs*32) P
c. 273+5GNA^ p.? [17] VUS
27 LMNA c.992GNA p.(Arg331Gln) P
28 PLN c.40_42delAGA p.(Arg14del) P
29 TTN c.55063del p.(Thr18355Leufs*3) LP
30 PLN c.40_42delAGA p.(Arg14del) P
Abbreviations (and used isoform for annotation, unless indicated otherwise below):
CRYAB (NM_001885.2) = crystallin alpha B; PLN (NM_002667.4) = phospholamban; LMNA
(NM_170707.3) = lamin A/C; TNNT2 (NM_000364.3) = troponin T type 2; TTN
(NM_133378.4) = titin; TPM1 (NM_000366.5) = tropomyosin 1;MYBPC3 (NM_000256.3):
myosin-binding protein C; MYH7 (NM_000257.3) = myosin heavy chain 7; DSP
(NM_004415.3) = desmoplakin.
P = pathogenic; LP = likely pathogenic; VUS variant of unknown signiﬁcance.
#NM_133379.4.
^splice site variant: sequence changes at protein level unknown.
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In the past decade, advances inmolecular genetics, that is, the devel-
opment and implementation of next-generation sequencing (NGS)
techniques, have allowed identiﬁcation of a still-increasing number of
variants related to human cardiomyopathies like hypertrophic, dilated
(DCM), and arrhythmogenic cardiomyopathy (ACM). ACM, and in par-
ticular its right dominant form arrhythmogenic right ventricular cardio-
myopathy (ARVC), is morphologically characterized by myocardial
atrophy due to ﬁbrofatty replacement of primarily right ventricular
myocardium and clinically by frequent and often early arrhythmogenic
events [1]. In ACM, pathogenic variants in over 13 genes [PKP2, DSP,
DSC2, DSG2, JUP, TGFB3, TMEM43, LMNA, DES, TTN, PLN, RYR2, CTNNA3]
[2] have been identiﬁed so far, of which pathogenic variants in genes
encoding desmosomal proteins (PKP2, DSP, DSC2, DSG2, JUP) comprise
the major part worldwide [3].
However, it appeared that the pathogenic nondesmosomal
c.40_42delAGA (p.Arg14del) variant in the phospholamban (PLN)
gene is the most prevalent cardiomyopathy-related mutation in the
Netherlands, being detected in 12% of patients clinically diagnosed
with ARVC and in 15% of DCM cases [4]. The pathogenic PLN p.Arg14del
variant was characterized as a Dutch founder mutation [5], but carriers
have also been found in several other European countries, Canada, and
the USA [6,7].
PLN is a transmembrane sarcoplasmic reticulum phosphoprotein
that regulates calcium cycling by inhibiting the cardiac isoform of the
sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) in cardiac myocytes.
In normal conditions, when phosphorylated, the inhibition of SERCA2a
is alleviated, and calcium ﬂux into the sarcoplasmic reticulum increases
[8]. The pathogenic PLN p.Arg14del variant has been shown to cause
superinhibition of SERCA2 leading to calcium overload, cardiomyocyte
damage and, eventually, to myocardial ﬁbrosis [9].
Detailed analyses, both clinical evaluation [4,10] and histopathologic
examination [11,12] ofwhole heart specimens, revealed that thepheno-
type of PLN p.Arg14del cardiomyopathy is often characterized by over-
lapping features of both DCM and ARVC supporting the concept of ACM
as a biventricular disease. Carriers are at high risk formalignant ventric-
ular arrhythmias and end-stage heart failurewith subsequent highmor-
tality. A poor prognosis is observed from late adolescence [10].
We showed that PLN p.Arg14del cardiomyopathy can be diagnosed
in explanted and autopsy hearts by PLN immunohistochemistry (IHC)
which shows speciﬁc PLN-containing aggregates that are concentrated
in cardiomyocytes in dense perinuclear aggresomes. Notably, aggre-
gates could only be detected in 2 out of 25 (8%) right ventricular
endomyocardial biopsies (RVEMB) cases in a second cohort [12].
The purpose of this study was to determine the sensitivity and
speciﬁcity of PLN IHC to diagnose PLN p.Arg14del cardiomyopathy in
the clinical setting, in a larger myocardial tissue specimen from the
apex of the left ventricle (LV) harvested during left ventricular assist
device (LVAD) implantation, in a cohort of genetic cardiomyopathy
cases.
2. Material and methods
2.1. Source population
Thirty myocardial biopsies from the apex of the LV were collected
and evaluated, obtained during LVAD implantation. These pathology
specimens were provided by the local tissue bank (“DPSWeb Palga” da-
tabase; coded) of the Departments of Pathology, University Medical
Center Groningen and University Medical Center Utrecht, the
Netherlands. Nine of these LVAD specimens were from heterozygous
carriers of the pathogenic PLN p.Arg14del variant, expected to harbor
PLN aggregates in cardiomyocytes. In order to establish the sensitivity
and speciﬁcity of identifying PLN-positive aggregates, PLN-IHC was
also performed on 21 LVAD myocardial specimens from geneticcardiomyopathy cases with other variants in cardiomyopathy-related
genes. These variants, identiﬁed during standard clinical care using
targetedNGS,were classiﬁed according to theAmerican College ofMed-
ical Genetics and Genomics and the Association forMolecular Pathology
recommendations [13]. In the 21 non-PLN cases, 18 pathogenic (P) or
likely pathogenic (LP) variants in cardiomyopathy-related genes were
found and ﬁve variants of unknown signiﬁcance in the following
genes: lamin A/C (LMNA; 7 P/LP), titin (TTN; 6 P/LP and 2 VUS, both
VUS in 1 patient), desmoplakin (DSP; 1 P/LP and 1 VUS, both in 1 pa-
tient), tropomyosin 1 (TPM1; 2 P/LP), crystallin alpha B (CRYAB; 1 P/
LP), myosin-binding protein C (MYBPC3; 1 VUS), myosin heavy chain
7 (MYH7; 1 VUS), and troponin T type 2 (TNNT2; 1 P/LP). Further details
of these observed genetic variants are shown in Table 1.2.2. Ethics statement
The study met the criteria of the code of conduct for responsible use
of human tissue that is used in the Netherlands (Dutch federation of
biomedical scientiﬁc societies; http://www.federa.org).
The study conformed to the principles of the Helsinki Declaration
and the institutional medical ethics committees; the collection of
the tissue was approved by the scientiﬁc advisory board of the
biobank of the University Medical Center Utrecht, Utrecht, the
Netherlands (protocol no. 12/387).
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IHC for PLN was performed to visualize PLN-containing protein ag-
gregates in cardiomyocytes. The mouse monoclonal antibody 2D12
(Abcam, Cambridge, MA, USA) was used in a dilution of 1: 10,000. Ap-
plying this strong dilution, strong immunostaining of PLN aggregates
was still easy to discern from the weaker background staining of PLN
in the cytoplasm of the cardiomyocytes. This antibody binds speciﬁcally
to PLN residues 7–13. IHC was performed on an automated immuno-
staining platform (Ventana Benchmark Ultra, VentanaMedical Systems,
Tucson, AZ, USA) using the CC1 standard antigen retrieval protocol (Tris
HCl buffer pH 9 for 1 h at 95 °C). Appropriate positive and negative con-
trols were used throughout. Speciﬁcally, for the PLN antibody, themyo-
cardium served as internal positive control. The PLN aggregates were
examined in PLN-immunostained sections in an area of 10 mm2 in
each case, corresponding to 40 high power ﬁeld (HPF; the ﬁeld of the
40× lens) using an Olympus BX40 microscope. The characteristic fea-
tures of these aggregates as described in our previous work [12], in par-
ticular the size, shape, and localization, were used to identify and
characterize the aggresomes. All LVAD specimens were examined by
two independent observers (WPtR and AJHS) of which one is an expe-
rienced cardiovascular pathologist.
3. Results
Immunohistochemical analysis revealed typical dense perinuclear
globular PLN-positive aggregates (representing aggresomes) in all 9
PLN p.Arg14del cases, while absent in all other specimens. The observed
number of these PLN aggregates per specimenwas highly variable (me-
dian of 3 per 10 mm2; range 2–89). A characteristic example of PLN ag-
gregates in cardiomyocytes is shown in Fig. 1. PLN-containing
aggregates in PLN p.Arg14del cardiomyopathy are large elongated glob-
ular cytoplasmic aggregates present perinuclearly, on one side or both
sides of the nucleus. In longitudinally sectioned cardiomyocytes, these
PLN-containing aggregates are most easily detected, whereas in trans-
versely sectioned cardiomyocytes, they are much more difﬁcult to rec-
ognize. We noted that cardiomyocytes with PLN aggregates often
showed diminished cytoplasmic PLN staining (Fig. 1). In 20 genetic car-
diomyopathy cases due to genetic variants other than PLN, no PLN-
stained aggregates were observed. In one non-PLN case [Case 14
(Table 1): carrier of the pathogenic c.1608+4A>G splice site variant
in the LMNA gen], one of the two observers misinterpreted PLN stainingFig. 1. Typical PLN immunostaining result in a PLN p.Arg14del mutation carrier: large
globular elongated perinuclear PLN-stained aggregates in several cardiomyocytes,
indicating aggresome formation, in apical LV myocardium sectioned longitudinally.
Notably, the cardiomyocytes with aggregates also show diminished cytoplasmic PLN.
(PLN-IHC staining, original magniﬁcation ×200).of heavily wrinkled nuclear membranes in transversely sectioned
cardiomyocytes as perinuclear PLN aggregates (Fig. 2). After review,
both investigators agreed that these pseudo-aggregates were con-
densed wrinkled nuclear membranes and not typical PLN-containing
aggresomes. Overall, in this LVAD cohort, PLN immunostaining was
found to have very high sensitivity (9/9: 100%) and speciﬁcity (20/21:
95%) for demonstration of PLN protein aggregates in PLN p.Arg14del
cardiomyopathy.
4. Discussion
Phospholamban p.Arg14del cardiomyopathy, which clinically pre-
sents as DCMand/or ACM, is characterized by large perinuclear PLNpro-
tein aggregates, which are detectable in complete heart specimens and
ultrastructurally appear to be aggresomes [12]. LVAD implantation is an
established treatment option and is becoming increasingly common in
selected cardiomyopathy patients with severe heart failure [14]. At the
stage of LVAD implantation, a genetic diagnosis, whichmay guide treat-
ment and referral of family members for further investigation, is fre-
quently not established yet. During implantation of the device, a part
of the apex of the LV becomes available for diagnostic purposes. In the
present study, we observed that the application of PLN IHC on these
LVmyocardial tissue fragments is a highly sensitive and speciﬁcmethod
for demonstration of PLN protein aggregates in PLN p.Arg14del cardio-
myopathy. Dense perinuclear globular PLN-positive aggregates,
representing aggresomes, were found in all 9 PLN p.Arg14del cases,
whereas in 20 non-PLN cases, aggregated PLN immunostaining was
not observed. This negative control group consisted of cases of genetic
cardiomyopathy, which were related to variants in LMNA (7 cases),
TTN (7 cases), TPM1 (2 cases), and CRYAB, DSP, MYBPC3, MYH7, and
TNNT2 (1 case each), expanding earlier observations. In one non-PLN
case, one of the two observers misinterpreted PLN staining of heavily
wrinkled nuclear membranes in cross-sectioned cardiomyocytes as
perinuclear PLN aggregates. This underscores the fact that, apart from
being a speciﬁc component of the sarcoplasmic reticulum, PLN is also
present in the nuclear envelope of cardiomyocytes, where it may be in-
volved in nuclear calcium handling [15].
In our initial histopathological study [12], perinuclear PLN aggre-
gates were found with IHC in all 20 examined whole heart specimens,
in both left and right ventricularmyocardium, of PLNp.Arg14del cardio-
myopathy. PLN IHCwas negative in four cases of genetic DCM, related to
variants in the LMNA, desmin (DES), RNA-binding motif protein 20Fig. 2. PLN staining of heavily wrinkled nuclear membranes in transversely sectioned
cardiomyocytes may give the false impression of perinuclear PLN-positive aggresomes
in rare cases (PLN-IHC staining, original magniﬁcation ×200; Case 14, Table 1).
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related to variants in desmosomal genes [4 in plakophilin-2 (PKP2), 1 in
desmocollin-2 (DSC2), 1 in junctional plakoglobin (JUP), and 1 in des-
moplakin (DSP)]. But when we examined RVEMB specimens of PLN
p.Arg14del mutation carriers applying the same method, aggregates
could only be detected in 2 out of 25 (8%) cases.
We found a striking difference between the observed number of PLN
aggresomes in LVAD specimens compared to RVEMB specimens. In all
nine LVAD specimens of the present study, at least two PLN-positive
aggresomes were found per 10 mm2; whereas, in our initial histopath-
ological study, PLN-containing aggresomeswere only present in 2 out of
25 (8%) of examined RVEMB cases. The larger size of the LVAD speci-
mens may be a major factor responsible for the observed difference. In
addition, two other factors can be held responsible for this much
lower sensitivity of PLN IHC in RVEMB specimens in comparison to
LVAD specimens. Firstly, the lower number of PLN aggregates per
mm2 and their patchy distribution in the RV wall and septum, and sec-
ondly, contraction band artifacts in cardiomyocytes of the RVEMB spec-
imens which hampers the visualization of PLN aggregates [12].
To conclude, PLN IHC analysis of LVADbiopsies from this genetic car-
diomyopathy cohort was found to be a highly sensitive and speciﬁc
method for demonstration of PLN protein aggregates in PLN p.Arg14del
cardiomyopathy. In clinical practice PLN IHC analysis of LVAD speci-
mens, in contrast to RVEMB specimens, can be of incremental value in
the diagnostic workup of this cardiomyopathy, even more so if genetic
analysis cannot or has not been performed yet.
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